Positron emission tomography/computed tomography evaluation of oncolytic virus therapy efficacy in melanoma

Over the recent years, there have been great advances in the treatment options for metastatic melanoma, which was historically a poor disease, with virtually no viable treatment options. Since 2010 –2011, this has dramatically changed with the introduction of targeted therapies and immune checkpoint blockade. Another recent breakthrough has been the approval of a first oncolytic viral immunotherapy. Talimogene laherparepvec (T-VEC) is a modified herpes simplex virus, type 1, which can be adm inistered intralesionally in cutaneous, subcutaneous (s.c.) or lymph nodes of unresectable melanoma patients at stage IIIB/C–IVM1A with such lesions.

Source: European Journal of Cancer - December 8, 2017 Category: Cancer & Oncology Authors: Viola Franke, Bernies van der Hiel, Bart A. van de Wiel, Willem M.C. Klop, Sylvia ter Meulen, Alexander C.J. van Akkooi Tags: Letter to the Editor Source Type: research